ASSESSMENT OF SERUM IRISIN IN OVERWEIGHT AND OBESE PATIENT WITH POLYCYSTIC OVARY SYNDROME
Keywords:
PCOS, Obese, Irisin.
Abstract
Background and Objective: Polycystic ovary syndrome (PCOS) is the most common endocrine disorder
affecting 10–15 % of women in reproductive age. The objective was to evaluate the effect of irisin in the
etiology of obese patient with PCOS.
Study Design and Methods: The study design its a case control study. This study involved fifty obese
ladies (50) with confirmed diagnosis of PCOS. The second group served as control group and included
forty apparently normal (non-polycystic ovary) obese ladies (40). The following main parameters were
measured: Fasting serum levels of total Cholesterol, triglyceride, high density lipoprotein-cholesterol,
low density lipoprotein– cholesterol, glycohaemoglobin (HbA1c%), Insulin , Testosterone, FSH, serum
LH and Irisin.
Results: The median serum Irisin was significantly higher among PCOS cases (119.1 ng/ml) compared to
healthy controls (74.7 ng/ml). The median serum FSH was significantly higher among PCOS cases (6.52
ng/ml ) compared to controls (4.72 ng/ml). Serum LH was obviously higher among PCOS cases (6.88
ng/ml) compared to controls (6.08 ng/ml). The mean pulse rate, blood WBC count and serum VLDL were
significantly higher (71.6/min, 8.3 mg/dl and 22.5 mg/dl respectively) in cases with PCOS compared to
controls (67.5/min, 7.2 mg/dl and 18.5 mg/dl respectively). Conversely, the serum HDL was significantly
lower among PCOS cases (43.8 mg/dl) compared to controls (48.4 mg/dl), serum testosterone showed
statistically non-significant differences.
Conclusion: Data of the present study showed that serum Irisin was significantly higher among PCOS
cases. These findings suggest important role of irisin as a biomarker for PCOS and an important factor in
the development of PCOS.
Downloads
Download data is not yet available.
References
Abdullah, Q.H. (2008): The value of cardiac hormone
(pro-brain natriuretic peptide) in thediagnosis
and prognosis of acute myocardial infarction
and congestive heart failure. Ph.D thesis
.University of Duhok, College of Medicine.; 5:
5
Abdulrazak , H., Alnakash, F., Nada, K. (2007).
Polycystic ovarian syndrome: the correlation
between the LH/FSH ratio and disease
manifestations.Middle East Fertility
Society Journal Vol; 12(1):35.
Albrecht, E., Norheim, F., Thiede, B. (2015): Irisin –
a myth rather than an exercise-inducible
myokine. Scientific Reports.;5(1):8889.
Ana L., Lunardi R., Flávia R., Oliveira's, R. (2019).
Recent advances in the understanding and
management of polycystic ovary syndrome.
8:565.
Barry, J. A., Kuczmierczyk, A. R and Hardiman, P. J.
(2011). Anxiety and depression in polycystic
ovary syndrome: a systematic review and
meta-analysis. Human reproduction, 26(9),
2442-2451.
Bing Yan., Xiulin Shi., Huijie Zhang., Lingling Pan.,
Zhimin Ma., Suhuan Liu. et al(2014):
Association of serum irisin with metabolic
syndrome in obese Chinese adults. Plos one.
9(4):94235 .
Bostanci, M. S., Akdemir, N., Cinemre, B.,
Cevrioglu, A. S., Ozden, S and Unal, O.
(2015). Serum irisin levels in patients with
polycystic ovary syndrome. Eur Rev Med
Pharmacol Sci, 19(23), 4462-8.
Boström, P., Wu, J., Jedrychowski, M. P., Korde, A.,
Ye, L., Lo, J. C and Kajimura, S. (2012). A
PGC1-α-dependent myokine that drives
brown-fat-like development of white fat and
thermogenesis. Nature, 481(7382), 463-468.
Bozdag, G., Mumusoglu, S., Zengin, D., Karabulut,
E., & Yildiz, B. O. (2016). The prevalence and phenotypic features of polycystic ovary
syndrome: a systematic review and meta-
analysis. Human Reproduction, 31(12), 2841-
2855.
Cassar, S., Misso, M. L., Hopkins, W. G., Shaw, C.
S., Teede, H. J., & Stepto, N. K. (2016).
Insulin resistance in polycystic ovary
syndrome: a systematic review and meta-
analysis of euglycaemic–hyperinsulinaemic
clamp studies. Human reproduction, 31(11),
2619-2631.
Chang, C. L., Huang, S. Y., Soong, Y. K., Cheng, P.
J., Wang, C. J., & Liang, I. T. (2014).
Circulating irisin and glucose-dependent
insulinotropic peptide are associated with the
development of polycystic ovary syndrome.
The Journal of Clinical Endocrinology &
Metabolism, 99(12), E2539-E2548.
Chang, C. L., Huang, S. Y., Hsu, Y. C., Chin, T. H.,
& Soong, Y. K. (2019). The serum level of
irisin, but not asprosin, is abnormal in
polycystic ovary syndrome patients. Scientific
reports, 9(1), 1-11.
Chen, J. Q., Huang, Y. Y., Gusdon, A. M., & Qu, S.
(2015). Irisin: a new molecular marker and
target in metabolic disorder. Lipids in health
and disease, 14(1), 2.
Daan, N. M., Jaspers, L., Koster, M. P. H.,
Broekmans, F. J. M., De Rijke, Y. B., Franco,
O. H., et al(2015). Androgen levels in women
with various forms of ovarian dysfunction:
associations with cardiometabolic features.
Human Reproduction, 30(10), 2376-2386.
Day, F., Karaderi, T., Jones, M. R., Meun, C., He, C.,
Drong, A., ... & Magi, R. (2018). Large-scale
genome-wide meta-analysis of polycystic
ovary syndrome suggests shared genetic
architecture for different diagnosis criteria.
PLoS genetics, 14(12), e1007813.
Diamanti-Kandarakis, E., & Dunaif, A. (2012).
Insulin resistance and the polycystic ovary
syndrome revisited: an update on mechanisms
and implications. Endocrine reviews, 33(6),
981-1030.
Elif G., Aylin Y., Bayram Y(2018).The effect of
nutrient supplementation in the management
of polycystic ovary syndrome-associated
metabolic dysfunctionsJ Turk Ger Gynecol
Assoc Dec; 19(4):220–232.
Escobar-Morreale, H. F., Luque-Ramírez, M., &
González, F. (2011). Circulating inflammatory
markers in polycystic ovary syndrome: a
systematic review and metaanalysis. Fertility
and sterility, 95(3), 1048-1058.
Foda, A. A., Foda, E. A., & Abel-Aal, I. (2018).
Serum Irisin levels as a marker in some
phenotypes of PCOS. Middle East Fertility
Society Journal, 23(2), 112-116.
Hotamisligil,G.S.(2006):Inflammation and metabolic
disorders. Nature. ;444(7121):860–7.
Ibrahim, M. H., Ahmed, S. A. A., Moety, A., Attiaa,
D., & Elsayed, S. F. (2018). The relation of
serum irisin level with metabolic and
hormonal changes in rat model of polycystic
ovary. zagazig university medical journal,
24(5), 409-419.
Jedrychowski, M. P., Wrann, C. D., Paulo, J. A.,
Gerber, K. K., Szpyt, J., Robinson, M. M. et al
(2015). Detection and quantitation of
circulating human irisin by tandem mass
spectrometry. Cell metabolism, 22(4), 734-
740.
Kurdiova, T., Balaz, M., Vician, M., Maderova, D.,
Vlcek, M., Valkovic, L. et al(2014). Effects of
obesity, diabetes and exercise on Fndc5 gene
expression and irisin release in human skeletal
muscle and adipose tissue: in vivo and in vitro
studies. The Journal of physiology, 592(5),
1091-1107.
Legro, R. S., Arslanian, S. A., Ehrmann, D. A.,
Hoeger, K. M., Murad, M. H., Pasquali, R. et
al (2013). Diagnosis and treatment of
polycystic ovary syndrome: an Endocrine
Society clinical practice guideline. The Journal
of Clinical Endocrinology & Metabolism,
98(12), 4565-4592.
Legro, R. S., Castracane, V. D., & Kauffman, R. P.
(2004). Detecting insulin resistance in
polycystic ovary syndrome: purposes and
pitfalls. Obstetrical & gynecological survey,
59(2), 141-154. Löffler, D., Müller, U., Scheuermann, K., Friebe, D.,
Gesing, J., Bielitz, J., ... & Körner, A. (2015).
Serum irisin levels are regulated by acute
strenuous exercise. The Journal of Clinical
Endocrinology & Metabolism, 100(4), 1289-
1299.
Manish G., Avinash A., Ambuj Y., Shuchi
C., Sukriti K., Ved P., Anil K., and Annesh
B.(2016). Prognostic Factors in Patients
Hospitalized with Diabetic Ketoacidosis.
Endocrinol Metabolism (Seoul). 31(3): 424–
432.
Minyan Li., Mengliu Yang., Xiaoxin Zhou., Xia
Fang., Wenjing Hu., Wei Zhu., Cong
Wang., Dongfang Liu., Shengbing Li., Hua
Liu. (2015):elevated circulating levels of irisin
and the effect of metformin treatment in
women with polycystic ovary syndrome. the
journal of clinical endocrinology &
metabolism.;100 ( 4): 1485–1493.
Munoz, M., Yessabel, I., Camarillo Romero, E. D. S.,
Garcia, G., & de Jesus, J. (2018). Irisin a novel
metabolic biomarker: present knowledge and
future directions. International journal of
endocrinology, 2018.
rio r, ., alomba, ., ascella, T., i Biase, .,
Manguso, ., Tauchmanov , ., ... ullo, .
(2005). The increase of leukocytes as a new
putative marker of low-grade chronic
inflammation and early cardiovascular risk in
polycystic ovary syndrome. The Journal of
Clinical Endocrinology & Metabolism, 90(1),
2-5.
Polak, K., Czyzyk, A., Simoncini, T., & Meczekalski,
B. (2017). New markers of insulin resistance
in polycystic ovary syndrome. Journal of
endocrinological investigation, 40(1), 1-8.
Qiu, S., Cai, X., Yin, H., Zügel, M., Sun, Z.,
Steinacker, J. M., & Schumann, U. (2016).
Association between circulating irisin and
insulin resistance in non-diabetic adults: a
meta-analysis. Metabolism, 65(6), 825-834.
Rotterdam(2004):ESHRE/ASRM-Sponsored PCOS
Consensus Workshop Group. Revised 2003
consensus on diagnostic criteria and long-term
health risks related to polycystic ovary
syndrome. Fertil. Steril.; 81(1): 19–25.
Salazar, M. R., Carbajal, H. A., Espeche, W. G.,
Dulbecco, C. A., Aizpurúa, M., Marillet, A.
G., ... & Reaven, G. M. (2011). Relationships
among insulin resistance, obesity, diagnosis of
the metabolic syndrome and cardio-metabolic
risk. Diabetes and Vascular Disease Research,
8(2), 109-116.
SestiG., AndreozziF., FiorentinoTV., ManninoGC.,
SciacquaA., MariniMA., et al.(2014):high
circulating irisin levels are associated with
insulin resistance and vascular atherosclerosis
in a cohort of non diabetic adult subjects Acta
Diabetol., 51 (5) : 705-713.
Sorlie, D.E. (1995): Medical biostatistics and
epidemiology: Examination and Board review.
1
st Edition. Connecticut, Appleton and Lang.
Noewalk. 47-88.
Wierman, M. E., Arlt, W., Basson, R., Davis, S. R.,
Miller, K. K., Murad, M. H., ... & Santoro, N.
(2014). Androgen therapy in women: a
reappraisal: an Endocrine Society clinical
practice guideline. The Journal of Clinical
Endocrinology & Metabolism, 99(10), 3489-
3510.
Zhao, L., Zhu, Z., Lou, H., Zhu, G., Huang, W.,
Zhang, S., & Liu, F. (2016). Polycystic ovary
syndrome (PCOS) and the risk of coronary
heart disease (CHD): a meta-analysis.
Oncotarget, 7(23), 33715.34.
(pro-brain natriuretic peptide) in thediagnosis
and prognosis of acute myocardial infarction
and congestive heart failure. Ph.D thesis
.University of Duhok, College of Medicine.; 5:
5
Abdulrazak , H., Alnakash, F., Nada, K. (2007).
Polycystic ovarian syndrome: the correlation
between the LH/FSH ratio and disease
manifestations.Middle East Fertility
Society Journal Vol; 12(1):35.
Albrecht, E., Norheim, F., Thiede, B. (2015): Irisin –
a myth rather than an exercise-inducible
myokine. Scientific Reports.;5(1):8889.
Ana L., Lunardi R., Flávia R., Oliveira's, R. (2019).
Recent advances in the understanding and
management of polycystic ovary syndrome.
8:565.
Barry, J. A., Kuczmierczyk, A. R and Hardiman, P. J.
(2011). Anxiety and depression in polycystic
ovary syndrome: a systematic review and
meta-analysis. Human reproduction, 26(9),
2442-2451.
Bing Yan., Xiulin Shi., Huijie Zhang., Lingling Pan.,
Zhimin Ma., Suhuan Liu. et al(2014):
Association of serum irisin with metabolic
syndrome in obese Chinese adults. Plos one.
9(4):94235 .
Bostanci, M. S., Akdemir, N., Cinemre, B.,
Cevrioglu, A. S., Ozden, S and Unal, O.
(2015). Serum irisin levels in patients with
polycystic ovary syndrome. Eur Rev Med
Pharmacol Sci, 19(23), 4462-8.
Boström, P., Wu, J., Jedrychowski, M. P., Korde, A.,
Ye, L., Lo, J. C and Kajimura, S. (2012). A
PGC1-α-dependent myokine that drives
brown-fat-like development of white fat and
thermogenesis. Nature, 481(7382), 463-468.
Bozdag, G., Mumusoglu, S., Zengin, D., Karabulut,
E., & Yildiz, B. O. (2016). The prevalence and phenotypic features of polycystic ovary
syndrome: a systematic review and meta-
analysis. Human Reproduction, 31(12), 2841-
2855.
Cassar, S., Misso, M. L., Hopkins, W. G., Shaw, C.
S., Teede, H. J., & Stepto, N. K. (2016).
Insulin resistance in polycystic ovary
syndrome: a systematic review and meta-
analysis of euglycaemic–hyperinsulinaemic
clamp studies. Human reproduction, 31(11),
2619-2631.
Chang, C. L., Huang, S. Y., Soong, Y. K., Cheng, P.
J., Wang, C. J., & Liang, I. T. (2014).
Circulating irisin and glucose-dependent
insulinotropic peptide are associated with the
development of polycystic ovary syndrome.
The Journal of Clinical Endocrinology &
Metabolism, 99(12), E2539-E2548.
Chang, C. L., Huang, S. Y., Hsu, Y. C., Chin, T. H.,
& Soong, Y. K. (2019). The serum level of
irisin, but not asprosin, is abnormal in
polycystic ovary syndrome patients. Scientific
reports, 9(1), 1-11.
Chen, J. Q., Huang, Y. Y., Gusdon, A. M., & Qu, S.
(2015). Irisin: a new molecular marker and
target in metabolic disorder. Lipids in health
and disease, 14(1), 2.
Daan, N. M., Jaspers, L., Koster, M. P. H.,
Broekmans, F. J. M., De Rijke, Y. B., Franco,
O. H., et al(2015). Androgen levels in women
with various forms of ovarian dysfunction:
associations with cardiometabolic features.
Human Reproduction, 30(10), 2376-2386.
Day, F., Karaderi, T., Jones, M. R., Meun, C., He, C.,
Drong, A., ... & Magi, R. (2018). Large-scale
genome-wide meta-analysis of polycystic
ovary syndrome suggests shared genetic
architecture for different diagnosis criteria.
PLoS genetics, 14(12), e1007813.
Diamanti-Kandarakis, E., & Dunaif, A. (2012).
Insulin resistance and the polycystic ovary
syndrome revisited: an update on mechanisms
and implications. Endocrine reviews, 33(6),
981-1030.
Elif G., Aylin Y., Bayram Y(2018).The effect of
nutrient supplementation in the management
of polycystic ovary syndrome-associated
metabolic dysfunctionsJ Turk Ger Gynecol
Assoc Dec; 19(4):220–232.
Escobar-Morreale, H. F., Luque-Ramírez, M., &
González, F. (2011). Circulating inflammatory
markers in polycystic ovary syndrome: a
systematic review and metaanalysis. Fertility
and sterility, 95(3), 1048-1058.
Foda, A. A., Foda, E. A., & Abel-Aal, I. (2018).
Serum Irisin levels as a marker in some
phenotypes of PCOS. Middle East Fertility
Society Journal, 23(2), 112-116.
Hotamisligil,G.S.(2006):Inflammation and metabolic
disorders. Nature. ;444(7121):860–7.
Ibrahim, M. H., Ahmed, S. A. A., Moety, A., Attiaa,
D., & Elsayed, S. F. (2018). The relation of
serum irisin level with metabolic and
hormonal changes in rat model of polycystic
ovary. zagazig university medical journal,
24(5), 409-419.
Jedrychowski, M. P., Wrann, C. D., Paulo, J. A.,
Gerber, K. K., Szpyt, J., Robinson, M. M. et al
(2015). Detection and quantitation of
circulating human irisin by tandem mass
spectrometry. Cell metabolism, 22(4), 734-
740.
Kurdiova, T., Balaz, M., Vician, M., Maderova, D.,
Vlcek, M., Valkovic, L. et al(2014). Effects of
obesity, diabetes and exercise on Fndc5 gene
expression and irisin release in human skeletal
muscle and adipose tissue: in vivo and in vitro
studies. The Journal of physiology, 592(5),
1091-1107.
Legro, R. S., Arslanian, S. A., Ehrmann, D. A.,
Hoeger, K. M., Murad, M. H., Pasquali, R. et
al (2013). Diagnosis and treatment of
polycystic ovary syndrome: an Endocrine
Society clinical practice guideline. The Journal
of Clinical Endocrinology & Metabolism,
98(12), 4565-4592.
Legro, R. S., Castracane, V. D., & Kauffman, R. P.
(2004). Detecting insulin resistance in
polycystic ovary syndrome: purposes and
pitfalls. Obstetrical & gynecological survey,
59(2), 141-154. Löffler, D., Müller, U., Scheuermann, K., Friebe, D.,
Gesing, J., Bielitz, J., ... & Körner, A. (2015).
Serum irisin levels are regulated by acute
strenuous exercise. The Journal of Clinical
Endocrinology & Metabolism, 100(4), 1289-
1299.
Manish G., Avinash A., Ambuj Y., Shuchi
C., Sukriti K., Ved P., Anil K., and Annesh
B.(2016). Prognostic Factors in Patients
Hospitalized with Diabetic Ketoacidosis.
Endocrinol Metabolism (Seoul). 31(3): 424–
432.
Minyan Li., Mengliu Yang., Xiaoxin Zhou., Xia
Fang., Wenjing Hu., Wei Zhu., Cong
Wang., Dongfang Liu., Shengbing Li., Hua
Liu. (2015):elevated circulating levels of irisin
and the effect of metformin treatment in
women with polycystic ovary syndrome. the
journal of clinical endocrinology &
metabolism.;100 ( 4): 1485–1493.
Munoz, M., Yessabel, I., Camarillo Romero, E. D. S.,
Garcia, G., & de Jesus, J. (2018). Irisin a novel
metabolic biomarker: present knowledge and
future directions. International journal of
endocrinology, 2018.
rio r, ., alomba, ., ascella, T., i Biase, .,
Manguso, ., Tauchmanov , ., ... ullo, .
(2005). The increase of leukocytes as a new
putative marker of low-grade chronic
inflammation and early cardiovascular risk in
polycystic ovary syndrome. The Journal of
Clinical Endocrinology & Metabolism, 90(1),
2-5.
Polak, K., Czyzyk, A., Simoncini, T., & Meczekalski,
B. (2017). New markers of insulin resistance
in polycystic ovary syndrome. Journal of
endocrinological investigation, 40(1), 1-8.
Qiu, S., Cai, X., Yin, H., Zügel, M., Sun, Z.,
Steinacker, J. M., & Schumann, U. (2016).
Association between circulating irisin and
insulin resistance in non-diabetic adults: a
meta-analysis. Metabolism, 65(6), 825-834.
Rotterdam(2004):ESHRE/ASRM-Sponsored PCOS
Consensus Workshop Group. Revised 2003
consensus on diagnostic criteria and long-term
health risks related to polycystic ovary
syndrome. Fertil. Steril.; 81(1): 19–25.
Salazar, M. R., Carbajal, H. A., Espeche, W. G.,
Dulbecco, C. A., Aizpurúa, M., Marillet, A.
G., ... & Reaven, G. M. (2011). Relationships
among insulin resistance, obesity, diagnosis of
the metabolic syndrome and cardio-metabolic
risk. Diabetes and Vascular Disease Research,
8(2), 109-116.
SestiG., AndreozziF., FiorentinoTV., ManninoGC.,
SciacquaA., MariniMA., et al.(2014):high
circulating irisin levels are associated with
insulin resistance and vascular atherosclerosis
in a cohort of non diabetic adult subjects Acta
Diabetol., 51 (5) : 705-713.
Sorlie, D.E. (1995): Medical biostatistics and
epidemiology: Examination and Board review.
1
st Edition. Connecticut, Appleton and Lang.
Noewalk. 47-88.
Wierman, M. E., Arlt, W., Basson, R., Davis, S. R.,
Miller, K. K., Murad, M. H., ... & Santoro, N.
(2014). Androgen therapy in women: a
reappraisal: an Endocrine Society clinical
practice guideline. The Journal of Clinical
Endocrinology & Metabolism, 99(10), 3489-
3510.
Zhao, L., Zhu, Z., Lou, H., Zhu, G., Huang, W.,
Zhang, S., & Liu, F. (2016). Polycystic ovary
syndrome (PCOS) and the risk of coronary
heart disease (CHD): a meta-analysis.
Oncotarget, 7(23), 33715.34.
Published
2020-12-09
How to Cite
MUSTAFA, S. Y., & IBRAHIM, S. A. (2020). ASSESSMENT OF SERUM IRISIN IN OVERWEIGHT AND OBESE PATIENT WITH POLYCYSTIC OVARY SYNDROME. Journal of Duhok University, 23(2), 25-35. https://doi.org/10.26682/sjuod.2020.23.2.3
Section
Pure and Engineering Sciences
It is the policy of the Journal of Duhok University to own the copyright of the technical contributions. It publishes and facilitates the appropriate re-utilize of the published materials by others. Photocopying is permitted with credit and referring to the source for individuals use.
Copyright © 2017. All Rights Reserved.
